Skip to content

Swiss Chinese Law Association — Geneva

SCLA | Swiss Chinese Law Association

Legal Observatory / Investment and Business

Legal Update Cross-Border Hong Kong SAR Rules in force

Hong Kong Admitted as 20th Regulatory Member of International Council for Harmonisation (ICH)

Hong Kong, China formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member on November 17, 2026.

What Changed

  • Hong Kong, China (represented by the Pharmacy and Poisons Board) became the 20th regulatory member of the ICH following assembly approval on November 17, 2026.
  • The HKSAR Government will establish the Centre for Medical Products Regulation (CMPR) in December 2026 to conduct independent primary drug evaluations under ICH standards.
  • Hong Kong's drug regulatory framework now integrates full ICH membership alongside its existing PIC/S membership effective since January 1, 2016.

Pharmaceutical companies, biotechnology developers, clinical research organisations, and regulatory affairs professionals operating in or targeting Hong Kong SAR are directly affected by Hong Kong’s official admission as a regulatory member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

On November 20, 2026, the Health Bureau of the Hong Kong Special Administrative Region (HKSAR) announced that Hong Kong, China—represented by the Pharmacy and Poisons Board of Hong Kong—was formally approved as the 20th regulatory member of the ICH. The admission was granted during the ICH assembly meeting held in the Czech Republic on November 17, 2026. This formal accession follows Hong Kong's admission as an ICH observer on October 31, 2023.

By attaining full regulatory membership, Hong Kong formally harmonises its technical standards for drug registration, safety, efficacy, and quality with the world's leading pharmaceutical regulatory authorities. These include the National Medical Products Administration of Mainland China, alongside regulatory bodies in Switzerland, the European Union, the United Kingdom, and the United States. Additionally, Hong Kong, China has been a full member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) since January 1, 2016.

To implement these regulatory capabilities, the HKSAR Government will establish the Centre for Medical Products Regulation (CMPR) in December 2026. The CMPR will build internal capacity for independent 'primary evaluation' and approval of innovative drugs, incorporating ICH technical requirements. This initiative aligns with the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026–2030) and dovetails with Mainland China’s National 15th Five-Year Plan.

This key milestone allows Hong Kong experts to participate actively in drafting international pharmaceutical guidelines, accelerating drug approval timelines, and furthering Hong Kong's progress toward becoming an international health and medical innovation hub.

Who May Be Affected

Pharmaceutical companies, biotechnology developers, clinical trial sponsors, medical product regulatory personnel, and research institutions in Hong Kong SAR, Mainland China, and international markets.

Cross-Border Context

Hong Kong's ICH membership complements its integration with Mainland China's 15th Five-Year Plan, and aligns its drug regulatory standards directly with regulatory authorities in Mainland China, Switzerland, the EU, the UK, and the US.

What to check next

  • Official launch details and operational structure of the Centre for Medical Products Regulation (CMPR) scheduled for December 2026.
  • Guidelines issued by the CMPR regarding independent primary evaluation requirements for innovative drugs in Hong Kong SAR.

This article provides general information and does not constitute legal advice. Consult the official text and obtain advice appropriate to your circumstances where needed.

Keep the issues that matter to you in view

Subscribe to SCLA updates and choose your interests.